Recently, a category-leading proof-of-concept study, “Targeted Detection of Cancer at the Cellular Level During Biopsy by Near-Infrared Confocal Laser Endomicroscopy,” was published in Nature Communications.
The study demonstrated the use of On Target’s intraoperative molecular imaging agent, CYTALUX™ (pafolacianine) injection, in conjunction with Mauna Kea’s U.S. FDA 510(k) cleared Cellvizio® platform for the detection of cancer cells during biopsy procedures. The new approach has the potential to help physicians diagnose lung cancer in earlier stages.
DocWire News spoke with Gregory Kennedy, MD, a resident in General Surgery at the University of Pennsylvania, and one of the study’s principal investigators, about the analysis and its implications.
